Novartis said its BTK inhibitor remibrutinib (Rhapsido) showed “superiority” in two Phase 3 multiple sclerosis studies, reporting reduced annualized relapse rates and inflammatory brain lesions versus Aubagio. The company also said the results showed clinically meaningful effects on disability progression and did not worsen liver safety, a key issue for BTK inhibitors in MS development.